Connor, Clark & Lunn Investment Management Ltd. Zentalis Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 229,138 shares of ZNTL stock, worth $513,269. This represents 0.0% of its overall portfolio holdings.
Number of Shares
229,138
Previous 101,270
126.26%
Holding current value
$513,269
Previous $414,000
102.9%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ZNTL
# of Institutions
143Shares Held
68MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$31.3 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$19.1 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$10.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$10.3 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$6.96 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $128M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...